ReviewBritish journal of cancer2017
Tumour microenvironment factors shaping the cancer metabolism landscape.
Review in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed.
- Patient-derived glioblastoma cultures preserve respiration phenotypes during ex vivo maintenance and show sex-associated differences in migration.Acta neuropathologica communications · 2026Article
- TNKS1 mediates the PTEN-PI3K/AKT pathway to regulate glycolysis and proliferation in gliomas.IBRO neuroscience reports · 2026Article
- Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.Medicina (Kaunas, Lithuania) · 2026Article
- The low-grade Inflammation Score (INFLA-Score) as a predictor of overall survival in prostate cancer: a UK biobank cohort study.BMC urology · 2026Article
- Purine salvage pathway protects CD8Nature immunology · 2026Article
- Breast Cancer in Relation to Dairy Product Consumption: A Review of Current Findings and Potential Mechanisms.Current nutrition reports · 2026Review
- Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.Scientific reports · 2026Article
- Circular RNAs: Key Regulators of Tumor Metabolic Reprogramming and Clinical Translation.Oncology research · 2026Review
- How Do Cancer Cells Fuse and Why?Advances in experimental medicine and biology · 2026Review
- Machine learning combined with body composition predicts surgical difficulty in mid-low rectal cancer surgery.Annals of medicine · 2025Article
- Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer.Journal of translational medicine · 2025Review
- PKM2-driven metabolic reprogramming in digestive system tumors: mechanisms, therapeutic advances, and clinical challenges.Frontiers in immunology · 2025Review
- Preoperative inflammatory burden index for prognostication in esophageal squamous cell carcinoma undergoing radical resection.Scientific reports · 2024Article
- Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies.Annals of hematology · 2024Review
- Article
- Beta hydroxybutyrate induces lung cancer cell death, mitochondrial impairment and oxidative stress in a long term glucose-restricted condition.Molecular biology reports · 2024Article
- STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines.Cancer gene therapy · 2024Article
- Single-cell RNA reveals a tumorigenic microenvironment in the interface zone of human breast tumors.Breast cancer research : BCR · 2023Article
- Cellular Adaptation Takes Advantage of Atavistic Regression Programs during Carcinogenesis.Cancers · 2023Review
- Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options.Current oncology (Toronto, Ont.) · 2023Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Cancer cells exhibit metabolic alterations that distinguish them from healthy tissues and make their metabolic processes susceptible to pharmacological targeting. Although typical cell-autonomous features of cancer metabolism have been emerging, it is increasingly appreciated that extrinsic factors also influence the metabolic properties of tumours. This review highlights evidence from the recent literature to discuss how conditions within the tumour microenvironment shape the metabolic character of tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.